Plasma proteome-driven discovery of therapeutic targets for age-related macular degeneration, identifying C3, CTRL, LCAT and TNFRSF10A as potential AMD drug targets, implicating lipid metabolism and cell death. #AMD#Genetics#Retina ๐ https://t.co/3lObxUQpB5
Over 1.1 million injections reveal no increased serious ocular safety risks with combined anti-complement and anti-VEGF therapy in AMD. #AMD#Retina#Complement#AntiVEGF ๐ https://t.co/Yh32gKTbkX
Could OCT transform #AMD monitoring? High-resolution imaging captures 87% of FAF features linked to geographic atrophy progression, and reveals additional RPE changes. #OCT#Retina#GA https://t.co/CEF1uxm10N
High-resolution #OCT reveals distinct deposits and RPE abnormalities in #AMD, offering potential new biomarkers for #GeographicAtrophy progression. #Retina#Ophthalmology https://t.co/rfnZJ9pfzu
New genetic evidence links dry #AMD to a 14% higher risk of #Alzheimers, highlighting shared complement and inflammatory pathways. #Neurodegeneration#Genetics https://t.co/1NyQBeaWqz
New #AMD study links higher systemic alternative complement activation with faster geographic atrophy growth, highlighting potential blood biomarkers. #GeographicAtrophy#Retina https://t.co/CxbnDFohCK
New genomic analyses link genetically predicted CETP-related HDL cholesterol to higher #AMD risk, strengthening evidence for lipid pathways in disease.
https://t.co/6jN3hMGDMb
#AMD#Retina#Genomics#LipidMetabolism#Ophthalmology
New research links PRPH2 mutations to early, sex-dependent complement activation and retinal degeneration, highlighting inflammation as a potential disease driver. #Retina#Complement#AMD
https://t.co/Dgm0mxsqQt
In a US study of 77 patients with geographic atrophy, preserving reading drove treatment choices and 86% preferred a one-time injection. https://t.co/Rc0MZvdGdF
#AMD#Retina#GeographicAtrophy
Come! Join us. ๐๏ธ
PhD positions available as part of the Doctoral Network 'PANDORA' on discovering Pathomechanisms and Novel Drug Optimization for AMD. Deadline 15th Oct.
Follow the link for details - https://t.co/zeZ8eOccHH
#PhD#research#AMD#complement#ophthalmology
MAC in the ageing choroid may be more widespread than expectedโhighest on macrophages, pericytes & smooth muscle cells. #AMD#Complement#Ophthalmology https://t.co/8B7pDov8Bv
Come! Join us. ๐๏ธ
PhD positions available as part of the Doctoral Network 'PANDORA' on discovering Pathomechanisms and Novel Drug Optimization for AMD. Deadline 15th Oct.
Follow the link for details - https://t.co/zeZ8eOccHH
#PhD#research#AMD#complement#ophthalmology
Could functional vision be the future of retinal gene-therapy approvals? Beaconโs VISTA win in XLRP puts patient-relevant vision outcomes centre stage. #GeneTherapy#Ophthalmology https://t.co/u1HJK6UdBe
Factor H deficiency reveals a potential complementโEVโmacrophage axis in kidney inflammation, opening new questions about how complement dysregulation drives tissue injury. #Complement#Immunology https://t.co/aEVHo8ZHix
Come! Join us. ๐๏ธ
PhD positions available as part of the Doctoral Network 'PANDORA' on discovering Pathomechanisms and Novel Drug Optimization for AMD. Deadline 15th Oct.
Follow the link for details - https://t.co/zeZ8eOccHH
#PhD#research#AMD#complement#ophthalmology
GOLDEN shows that systemic factor B suppression can engage complement without slowing GA progressionโan important lesson for complement-targeted AMD therapy. #AMD#Complement#Retina#DrugDevelopment https://t.co/MN5A01A3iM
AI may transform AMD drug discovery, but algorithms generate hypotheses, not biological proof. Validation, generalisability and mechanism remain the real tests. #AI#AMD#DrugDiscovery https://t.co/HjINrsZYq5
ADARxโs planned IPO could signal growing confidence in complement therapeutic, with a CFB-targeting siRNA advancing into AMD geographic atrophy. Could durable complement suppression be the next step for AMD? #AMD#Complement#siRNA#GeneSilencing https://t.co/hwxLERXClB